Related Experiment Video
Updated: Sep 20, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Adherence to Multidisciplinary Tumor Board Recommendations and Its Association with Survival: A Retrospective
Esin Aysel Kandemir1, Julia Roeper2, Heiner Zimmermann2
1School of Medicine and Health Sciences, University Department Internal Medicine-Oncology, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany. esin.aysel.kandemir@uni-oldenburg.de.
Purpose:
Multidisciplinary tumor boards (MTBs) intend to increase the quality of cancer care. Research on the association of adherence to MTB recommendations with survival is limited. This study aims to determine the impact of adherence to MTB recommendations on survival in colorectal cancer patients.
Methods:
This is a retrospective, observational study including patients diagnosed between 01.01.2014 and 31.12.2018. Electronic health records were reviewed to determine the adherence. Study endpoints were adherence rate, disease-free survival (DFS), and overall survival (OS). Follow-up was performed until 12.12.2023.
Results:
There was a significant difference in DFS (median DFS: 79 months [95% CI, 73-89] vs 22 months [95% CI, 17-87]) and OS (median OS: 78 months [95% CI, 75-86] vs 65 months [95% CI, 28-NR]) between the adherent group (n=406) versus the non-adherent group (n=52) (log-rank test, p<0.05). Performance status, stage and non-adherence were independent predictors of survival in the multivariate analysis (p<0.05 for all). The most common reason for non-adherence was patient preference (n=23).
Conclusion:
While MTBs have become an indispensable part of clinical practice, adherence to MTB recommendations was crucial to achieve survival benefit in this study. Patient preference should be prospectively analyzed from a patient and caregiver perspective in future studies.
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

